Roche Holding AG (OTCMKTS:RHHBY - Get Free Report) shares hit a new 52-week high during mid-day trading on Monday . The company traded as high as $44.31 and last traded at $44.24, with a volume of 7251897 shares. The stock had previously closed at $43.26.
Analysts Set New Price Targets
A number of equities analysts recently commented on the company. Sanford C. Bernstein raised Roche to a "strong-buy" rating in a research note on Thursday, January 30th. UBS Group upgraded shares of Roche from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. Finally, Morgan Stanley assumed coverage on Roche in a research report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Roche has an average rating of "Moderate Buy".
Check Out Our Latest Report on RHHBY
Roche Trading Up 0.1 %
The stock's 50-day moving average price is $40.40 and its 200-day moving average price is $38.60. The company has a current ratio of 1.26, a quick ratio of 0.97 and a debt-to-equity ratio of 0.86.
Hedge Funds Weigh In On Roche
A number of institutional investors have recently modified their holdings of RHHBY. Canopy Partners LLC raised its holdings in Roche by 4.6% during the third quarter. Canopy Partners LLC now owns 7,772 shares of the company's stock worth $310,000 after buying an additional 344 shares during the last quarter. Brooklyn Investment Group acquired a new stake in shares of Roche in the 3rd quarter worth about $40,000. IHT Wealth Management LLC acquired a new position in Roche during the 3rd quarter valued at about $236,000. Bard Financial Services Inc. increased its holdings in Roche by 156.8% during the 3rd quarter. Bard Financial Services Inc. now owns 80,500 shares of the company's stock worth $3,216,000 after purchasing an additional 49,150 shares in the last quarter. Finally, Confluence Investment Management LLC raised its stake in shares of Roche by 26.3% in the fourth quarter. Confluence Investment Management LLC now owns 13,981 shares of the company's stock worth $488,000 after purchasing an additional 2,910 shares during the last quarter.
About Roche
(
Get Free Report)
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.
Featured Stories
Before you consider Roche, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roche wasn't on the list.
While Roche currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
